Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Impact on TMAO in ESRD
NCT02738905Phase 1Withdrawn
- Start
- Jan 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rifaximin in end stage renal disease (ESRD). Primary endpoint: Change in serum trimethylamine-N-oxide levels at 7 days. Planned start Jan 2016; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT02738905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738905.